Ann: Mesoblast to File BLA for Ryoncil FDA Approval Next Week, page-134

I have been one of the more critical in his performance AS A CEO, and that stems from mainly the last AGM but prior in his attempts to bully the FDA as a novice CEO over the instructions they gave him after the first rejection.

The whole premiss of that costing lives has been an argument that has resulted in more children dying and the therapy being delayed once again.

If you were to ask any successful operation what the very key element was to their success, the answer to that, and also of every failure, is communication, or lack of.